Systemic scleroderma – Diagnostics – Overview of Information and Clinical Research

Systemic scleroderma, also known as systemic sclerosis, is a rare autoimmune condition where the body produces too much collagen, causing skin and internal organs to become thick and hardened. Early recognition and proper testing are essential, as this condition can affect multiple body systems and lead to serious complications if not identified and managed promptly.

Introduction: Who Should Undergo Diagnostics

Diagnosing systemic scleroderma can be quite complex because the condition presents differently in each person and its symptoms can resemble those of many other diseases. If you notice certain warning signs, it is important to seek medical evaluation as soon as possible. The earlier the diagnosis, the better the chances of managing symptoms and preventing serious organ damage.^[1]

You should consider getting tested if you experience repeated episodes of your fingers or toes turning white, blue, or red when exposed to cold temperatures or stress. This phenomenon, called Raynaud’s phenomenon, is often one of the first signs of systemic scleroderma and can appear weeks or even years before other symptoms develop.^[4] Another early indicator is swelling in your hands, which may be followed by skin that begins to feel tight, thick, or unusually shiny, particularly on your fingers, hands, or face.^[1]

It is advisable to visit a healthcare provider if you notice hardening or tightening of your skin in multiple areas of your body, especially if this is accompanied by joint pain, stiffness, or difficulty moving your fingers. Some people also develop small painful sores on their fingertips, red spots on their skin, or hard bumps under the skin caused by calcium deposits.^[2] These symptoms should not be ignored, as they may indicate that your immune system is attacking your body’s own tissues.

People who experience persistent heartburn, difficulty swallowing, unexplained shortness of breath, or ongoing fatigue should also seek medical attention. These symptoms can suggest that systemic scleroderma is affecting internal organs such as the esophagus, lungs, heart, or kidneys.^[5] Because the disease can lead to life-threatening complications when organs are involved, early diagnosis through proper testing becomes even more critical.

⚠️ Important

Women between the ages of 30 and 50 are at higher risk of developing systemic scleroderma and should be especially vigilant about symptoms. However, the condition can affect anyone, including children and men. If you have a family member with scleroderma or another autoimmune disease, your risk may be slightly higher, and you should discuss this with your doctor.^[4]

Classic Diagnostic Methods

When you visit a doctor with concerns about possible systemic scleroderma, the diagnostic process typically begins with a thorough conversation about your symptoms and a detailed physical examination. Your doctor will ask about when your symptoms started, what parts of your body are affected, and whether you have noticed any changes over time. They will carefully examine your skin, looking for areas of thickening, tightness, or discoloration, and will check your hands, face, arms, and legs for characteristic changes.^[9]

One of the most important early diagnostic tools is blood testing. Your doctor will likely order tests to check for elevated levels of certain antibodies, which are proteins made by your immune system. In systemic scleroderma, the immune system produces specific antibodies that can help confirm the diagnosis and even predict which type of the disease you might have.^[9] The most commonly tested antibody is the antinuclear antibody (ANA), which is present in most people with systemic sclerosis.^[22]

Beyond the basic ANA test, more specific antibody tests can provide valuable information. For example, people with limited cutaneous systemic sclerosis often have anti-centromere antibodies in their blood. Those with diffuse cutaneous systemic sclerosis are more likely to have anti-topoisomerase antibodies, also called Scl-70 antibodies, or anti-RNA polymerase antibodies. These specific antibodies not only help confirm the diagnosis but also give doctors clues about which organs might be at risk and how the disease might progress.^[22]

Your doctor may also perform a special examination called nail-fold capillary microscopy. This is a simple, painless test where a doctor uses a special magnifying instrument to look at the tiny blood vessels at the base of your fingernails. In people with systemic scleroderma, these small blood vessels often show characteristic abnormalities, such as widening or loss of normal structure, which can help support the diagnosis.^[12]

To assess whether internal organs are affected, several additional tests may be necessary. If your doctor suspects lung involvement, you will likely undergo pulmonary function tests to measure how well your lungs are working. These tests involve breathing into a machine that measures the volume and flow of air you can move in and out of your lungs.^[12] High-resolution computed tomography, or CT scans of the chest, may also be performed to look for signs of scarring or inflammation in the lung tissue, a condition called interstitial lung disease.^[9]

Heart involvement can be evaluated using several methods. An electrocardiogram (ECG) records the electrical activity of your heart and can detect rhythm problems or damage to the heart muscle. An echocardiogram is an ultrasound of the heart that creates moving pictures, allowing doctors to see how well your heart is pumping and whether there is increased pressure in the blood vessels of your lungs, a serious complication called pulmonary arterial hypertension.^[12]

If digestive symptoms are present, such as difficulty swallowing or severe heartburn, your doctor might recommend tests to examine your esophagus and stomach. These could include imaging tests like a barium swallow, where you drink a special liquid that shows up on X-rays, or an endoscopy, where a thin, flexible tube with a camera is passed down your throat to directly view the inside of your digestive tract.^[9]

Kidney function is monitored through regular blood tests that measure levels of substances like creatinine and through urine tests. Blood pressure checks are also critically important, as sudden high blood pressure can signal a dangerous complication called scleroderma renal crisis, which requires immediate treatment.^[9]

In some cases, particularly when the diagnosis is uncertain or when doctors want to understand the extent of skin or organ involvement, a skin biopsy may be performed. This involves removing a small sample of skin tissue, which is then examined under a microscope to look for the characteristic changes of scleroderma, such as excessive collagen buildup and tissue scarring.^[12]

⚠️ Important

Because systemic scleroderma can affect multiple organ systems, diagnosis and ongoing monitoring require a team approach. You may need to see several specialists, including a rheumatologist who specializes in autoimmune diseases, a pulmonologist for lung issues, a cardiologist for heart concerns, a gastroenterologist for digestive problems, and a dermatologist for skin changes. Regular follow-up appointments and repeat testing are essential to catch complications early.^[12]

Diagnostics for Clinical Trial Qualification

When patients with systemic scleroderma are considered for participation in clinical trials, they typically undergo a more extensive and standardized set of diagnostic tests than in routine clinical care. These tests serve multiple purposes: they help researchers confirm that patients truly have the disease, determine the severity and type of scleroderma, identify which organs are affected, and establish a baseline against which treatment effects can be measured.^[13]

One of the most commonly used assessments in clinical trials is the modified Rodnan skin score. This is a standardized method where a trained healthcare provider examines 17 different areas of the body and rates the thickness of the skin on a scale from zero to three at each site. The scores are then added together to give a total score that reflects the extent and severity of skin involvement. This scoring system is considered an essential measure in trials testing treatments aimed at reducing skin thickening.^[13]

Lung function testing is another critical component of clinical trial screening, particularly for studies focusing on lung complications. Participants undergo pulmonary function tests to measure their forced vital capacity (FVC), which is the total amount of air you can forcefully exhale after taking the deepest breath possible. A decline in FVC is a key indicator that lung scarring is worsening. Many trials also measure the diffusing capacity of the lungs for carbon monoxide (DLCO), which assesses how well oxygen moves from the lungs into the bloodstream.^[13]

High-resolution CT scans of the chest are often required in trials studying interstitial lung disease. These detailed images allow researchers to see and measure the extent of lung scarring at the beginning of the trial and to track changes over time. The images are sometimes analyzed using specialized computer software to quantify the amount of affected lung tissue.^[13]

For clinical trials investigating treatments for pulmonary arterial hypertension, patients must undergo right heart catheterization. This is an invasive test where a thin tube is inserted through a vein and guided into the heart and pulmonary arteries. It directly measures the pressure in these blood vessels, which is the definitive way to diagnose pulmonary arterial hypertension. Additionally, echocardiography is performed to estimate pressures non-invasively and to assess heart function.^[13]

Antibody testing is standard in clinical trial qualification because certain antibodies are associated with different disease patterns and risks. Knowing a patient’s antibody profile helps researchers create more homogeneous study groups and can predict who is more likely to develop certain complications. Tests for anti-centromere, anti-topoisomerase (Scl-70), and anti-RNA polymerase III antibodies are typically included.^[12]

Kidney function is carefully assessed through blood tests measuring creatinine levels and estimated glomerular filtration rate, as well as through urine tests that check for protein in the urine. Regular blood pressure measurements are also mandatory, as certain clinical trials may exclude patients with poorly controlled blood pressure or a history of renal crisis.^[12]

Some clinical trials, especially those studying disease-modifying therapies or stem cell transplantation, require very detailed assessments of overall health and organ function. This may include comprehensive blood work to check blood cell counts, liver function, inflammatory markers, and immune system components. Cardiac assessments may include electrocardiograms, echocardiograms, and sometimes more advanced imaging like cardiac MRI to detect any heart muscle involvement.^[14]

Quality of life assessments and functional ability questionnaires are also important components of clinical trial screening and monitoring. Patients may be asked to complete validated questionnaires about their pain levels, fatigue, ability to perform daily activities, and overall well-being. These patient-reported outcomes help researchers understand not just whether a treatment affects measurable disease parameters, but whether it actually improves patients’ lives.^[13]

For trials investigating newer therapies such as CAR T-cell therapy, which involves modifying a patient’s own immune cells to target disease-causing B cells, additional specialized tests are required. These may include detailed assessments of the immune system, bone marrow evaluation, and tests to ensure that patients are healthy enough to undergo this intensive treatment approach.^[15]

It is worth noting that participation in clinical trials often requires patients to undergo these tests repeatedly throughout the study period, not just at the beginning. This regular monitoring allows researchers to track disease progression, detect any side effects of the treatment being tested, and gather the data needed to determine whether a new therapy is safe and effective. While this can be time-consuming and sometimes uncomfortable for participants, it also means that patients in trials receive very close medical attention and access to potentially beneficial new treatments before they become widely available.^[13]

Prognosis and Survival Rate

Prognosis

The outlook for people with systemic scleroderma varies considerably depending on which type of the disease they have and which organs are affected. Understanding the prognosis requires recognizing that systemic sclerosis is a spectrum condition, with some forms being relatively mild and others potentially life-threatening.^[8]

People with limited cutaneous systemic sclerosis, where skin involvement is restricted to the hands, arms below the elbows, legs below the knees, and face, generally have a better prognosis than those with the diffuse form. This type tends to progress more slowly, and while internal organ complications can occur, they often develop years after the initial skin symptoms appear. Many people with limited disease can maintain good quality of life with appropriate management.^[8]

In contrast, diffuse cutaneous systemic sclerosis, which affects larger areas of skin including the trunk and upper arms and legs, typically progresses more rapidly and carries a higher risk of serious organ involvement early in the disease course. People with diffuse disease are more likely to develop interstitial lung disease, heart complications, and kidney problems within the first few years after diagnosis.^[8]

Several factors influence prognosis. The extent of skin involvement, as measured by skin scores, correlates with the likelihood of internal organ complications. The specific antibodies present in a person’s blood also provide prognostic information. For example, anti-RNA polymerase III antibodies are associated with a higher risk of kidney crisis but may also indicate a better long-term prognosis if the crisis is successfully managed. Anti-topoisomerase antibodies are linked to more severe lung disease.^[22]

The most serious determinants of prognosis are lung involvement and heart complications. Interstitial lung disease and pulmonary arterial hypertension are now the leading causes of death in people with systemic scleroderma. However, with modern treatments and careful monitoring, the outlook for these complications has improved significantly over the past two decades. Early detection through regular screening allows for timely intervention before irreversible damage occurs.^[8]

Kidney involvement, particularly scleroderma renal crisis, was once a major cause of death but has become much more manageable with medications called ACE inhibitors. When treated promptly, most people survive a renal crisis, although some may require temporary or permanent dialysis.^[8]

Age at diagnosis also plays a role in prognosis. People diagnosed at a younger age sometimes face unique challenges, including the psychological impact of living with a chronic disease during formative years, but they may also respond better to aggressive treatments. Older individuals may have more comorbid conditions that complicate management.^[19]

Overall, with advances in understanding the disease and improvements in treatment options, many people with systemic scleroderma can now lead long and fulfilling lives. The key factors in achieving the best possible outcome are early diagnosis, close monitoring for organ involvement, prompt treatment of complications, and comprehensive care from a team of specialists experienced in managing scleroderma.^[12]

Survival Rate

The survival rates for systemic scleroderma have improved substantially over the past several decades, largely due to better recognition and treatment of organ complications. The estimated prevalence of the disease ranges from 50 to 300 cases per one million people, and it primarily affects women, who are four times more likely to develop the condition than men.^[4]

Historical data showed that systemic sclerosis had significant mortality, but modern studies indicate much better outcomes. The type of disease significantly impacts survival. People with limited cutaneous systemic sclerosis tend to have survival rates that approach those of the general population, particularly if they do not develop severe internal organ complications. Their disease often remains stable for long periods, and many live normal life spans.^[8]

Diffuse cutaneous systemic sclerosis carries a more serious prognosis. Studies indicate that survival rates are lower in this group, particularly in the first few years after diagnosis when the risk of rapidly progressive organ involvement is highest. However, even in diffuse disease, those who make it through the early high-risk period without major organ complications often see their disease stabilize and may experience improvement over time.^[8]

The most significant factor affecting survival is the development of lung or heart complications. Interstitial lung disease and pulmonary arterial hypertension are now the leading causes of death in systemic sclerosis, accounting for a large proportion of scleroderma-related mortality. Without treatment, pulmonary arterial hypertension has a particularly poor prognosis, but modern therapies have dramatically improved survival for people with this complication.^[8]

Scleroderma renal crisis, once responsible for many deaths, is now much more survivable thanks to effective blood pressure medications. With prompt recognition and treatment, most people survive a renal crisis, although long-term kidney function may be affected in some cases.^[8]

For patients with severe, progressive disease, particularly those with diffuse cutaneous disease and significant lung involvement, more aggressive treatment options such as autologous hematopoietic stem cell transplantation have been shown to improve survival compared to conventional therapy. While this treatment carries its own risks, studies have demonstrated better long-term outcomes for carefully selected patients.^[15]

It is important to emphasize that survival statistics represent averages across large groups of patients and cannot predict what will happen to any individual. Many factors influence outcomes, including how early the disease is detected, how aggressively it is treated, access to specialized care, and individual patient characteristics. Regular monitoring and proactive management of complications have become the cornerstones of improving both survival and quality of life for people living with systemic scleroderma.^[12]

#1 Clinical Trials Search in Europe